Details of the Drug Combination

General Information of Drug Combination (ID: DCPHSFU)

Drug Combination Name
Flavopiridol Mitoxantrone
Indication
Disease Entry Status REF
Adult Acute Megakaryoblastic Leukemia (M7) Phase 1 [1]
Component Drugs Flavopiridol   DMKSUOI Mitoxantrone   DMM39BF
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Flavopiridol
Disease Entry ICD 11 Status REF
Acute myeloid leukaemia 2A60 Phase 2 [2]
Chronic lymphocytic leukaemia 2A82.0 Discontinued in Phase 3 [3]
Flavopiridol Interacts with 3 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Cyclin-dependent kinase 9 (CDK9) TT1LVF2 CDK9_HUMAN Inhibitor [6]
Cyclin-dependent kinase (CDK) TTMBO1Z NOUNIPROTAC Inhibitor [9]
Myophosphorylase (PYGM) TT31JXP PYGM_HUMAN Inhibitor [9]
------------------------------------------------------------------------------------
Flavopiridol Interacts with 2 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [10]
Organic anion transporting polypeptide 1B1 (SLCO1B1) DT3D8F0 SO1B1_HUMAN Substrate [11]
------------------------------------------------------------------------------------
Flavopiridol Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
UDP-glucuronosyltransferase 1A1 (UGT1A1) DEYGVN4 UD11_HUMAN Metabolism [12]
------------------------------------------------------------------------------------
Flavopiridol Interacts with 42 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Tumor necrosis factor receptor superfamily member 10A (TNFRSF10A) OTBPCU2O TR10A_HUMAN Increases Expression [13]
Tumor necrosis factor receptor superfamily member 10B (TNFRSF10B) OTA1CPBV TR10B_HUMAN Increases Expression [13]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Decreases Expression [8]
CASP8 and FADD-like apoptosis regulator (CFLAR) OTX14BAS CFLAR_HUMAN Decreases Expression [14]
Serine protease HTRA2, mitochondrial (HTRA2) OTC7616F HTRA2_HUMAN Affects Localization [8]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Decreases Activity [15]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Decreases Expression [16]
Retinoblastoma-associated protein (RB1) OTQJUJMZ RB_HUMAN Decreases Activity [17]
Cyclin-dependent kinase 1 (CDK1) OTW1SC2N CDK1_HUMAN Decreases Activity [8]
Poly polymerase 1 (PARP1) OT310QSG PARP1_HUMAN Increases Cleavage [18]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [19]
Mast/stem cell growth factor receptor Kit (KIT) OTHUY3VZ KIT_HUMAN Decreases Expression [20]
Cyclin-dependent kinase 4 (CDK4) OT7EP05T CDK4_HUMAN Decreases Activity [8]
Proliferating cell nuclear antigen (PCNA) OTHZ1RIA PCNA_HUMAN Decreases Activity [17]
G2/mitotic-specific cyclin-B1 (CCNB1) OT19S7E5 CCNB1_HUMAN Decreases Expression [8]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Affects Expression [21]
High mobility group protein HMG-I/HMG-Y (HMGA1) OTQUSHPX HMGA1_HUMAN Decreases Expression [7]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Decreases Activity [17]
G1/S-specific cyclin-E1 (CCNE1) OTLD7UID CCNE1_HUMAN Decreases Expression [22]
DNA-directed RNA polymerase II subunit RPB1 (POLR2A) OTHJQ1DZ RPB1_HUMAN Decreases Expression [7]
Cyclin-dependent kinase 2 (CDK2) OTB5DYYZ CDK2_HUMAN Decreases Activity [8]
NF-kappa-B inhibitor alpha (NFKBIA) OTFT924M IKBA_HUMAN Increases Expression [23]
Retinoblastoma-like protein 1 (RBL1) OTDEBFYC RBL1_HUMAN Decreases Expression [24]
Cyclin-dependent kinase inhibitor 1 (CDKN1A) OTQWHCZE CDN1A_HUMAN Decreases Expression [22]
Signal transducer and activator of transcription 3 (STAT3) OTAAGKYZ STAT3_HUMAN Decreases Expression [7]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [25]
Cyclin-dependent kinase inhibitor 1B (CDKN1B) OTNY5LLZ CDN1B_HUMAN Increases Cleavage [26]
Tumor necrosis factor ligand superfamily member 10 (TNFSF10) OT4PXBTA TNF10_HUMAN Increases Expression [13]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [18]
BH3-interacting domain death agonist (BID) OTOSHSHU BID_HUMAN Increases Cleavage [27]
Cytochrome c (CYCS) OTBFALJD CYC_HUMAN Affects Localization [18]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Decreases Expression [28]
Transcription factor E2F1 (E2F1) OTLKYBBC E2F1_HUMAN Decreases Expression [7]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [28]
Bcl-2-like protein 1 (BCL2L1) OTRC5K9O B2CL1_HUMAN Decreases Expression [8]
Induced myeloid leukemia cell differentiation protein Mcl-1 (MCL1) OT2YYI1A MCL1_HUMAN Decreases Expression [8]
Baculoviral IAP repeat-containing protein 3 (BIRC3) OT3E95KB BIRC3_HUMAN Decreases Expression [8]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Cleavage [29]
BAG family molecular chaperone regulator 1 (BAG1) OTRQNIA4 BAG1_HUMAN Decreases Expression [19]
Diablo IAP-binding mitochondrial protein (DIABLO) OTHJ9MCZ DBLOH_HUMAN Affects Localization [8]
Glycogen phosphorylase, brain form (PYGB) OT2ZTJT0 PYGB_HUMAN Affects Binding [30]
Glycogen phosphorylase, liver form (PYGL) OTS1YFGR PYGL_HUMAN Affects Binding [30]
------------------------------------------------------------------------------------
⏷ Show the Full List of 42 DOT(s)
Indication(s) of Mitoxantrone
Disease Entry ICD 11 Status REF
Acute myelogenous leukaemia 2A41 Approved [4]
Adult acute monocytic leukemia N.A. Approved [4]
Leukemia N.A. Approved [4]
Solid tumour/cancer 2A00-2F9Z Approved [5]
Non-hodgkin lymphoma 2B33.5 Phase 1/2 [6]
Metastatic prostate carcinoma N.A. Investigative [4]
Mitoxantrone Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
DNA topoisomerase II (TOP2) TT0IHXV TOP2A_HUMAN; TOP2B_HUMAN Modulator [34]
------------------------------------------------------------------------------------
Mitoxantrone Interacts with 5 DTP Molecule(s)
DTP Name DTP ID UniProt ID Mode of Action REF
Multidrug resistance-associated protein 1 (ABCC1) DTSYQGK MRP1_HUMAN Substrate [35]
Multidrug resistance-associated protein 2 (ABCC2) DTFI42L MRP2_HUMAN Substrate [36]
P-glycoprotein 1 (ABCB1) DTUGYRD MDR1_HUMAN Substrate [36]
Breast cancer resistance protein (ABCG2) DTI7UX6 ABCG2_HUMAN Substrate [37]
ATP-binding cassette sub-family A member 3 (ABCA3) DT2T6VQ ABCA3_HUMAN Substrate [38]
------------------------------------------------------------------------------------
Mitoxantrone Interacts with 1 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 2E1 (CYP2E1) DEVDYN7 CP2E1_HUMAN Metabolism [39]
------------------------------------------------------------------------------------
Mitoxantrone Interacts with 230 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Broad substrate specificity ATP-binding cassette transporter ABCG2 (ABCG2) OTW8V2V1 ABCG2_HUMAN Increases Expression [40]
ATP-dependent translocase ABCB1 (ABCB1) OTEJROBO MDR1_HUMAN Increases Expression [40]
Transcription factor Jun (JUN) OTCYBO6X JUN_HUMAN Increases Expression [41]
Voltage-dependent T-type calcium channel subunit alpha-1G (CACNA1G) OTGKBRE4 CAC1G_HUMAN Decreases Expression [31]
Tyrosine-protein kinase JAK2 (JAK2) OTBIDOOR JAK2_HUMAN Decreases Expression [31]
Sodium channel subunit beta-2 (SCN2B) OTFAHJ38 SCN2B_HUMAN Decreases Expression [31]
LIM domain-binding protein 3 (LDB3) OTGQL1AM LDB3_HUMAN Decreases Expression [31]
Creatine kinase M-type (CKM) OTME0KO7 KCRM_HUMAN Decreases Expression [31]
Glutathione peroxidase 1 (GPX1) OTE2O72Q GPX1_HUMAN Increases Expression [31]
Glycogen phosphorylase, muscle form (PYGM) OTWLVWTV PYGM_HUMAN Decreases Expression [31]
Dystrophin (DMD) OTD21T5J DMD_HUMAN Decreases Expression [31]
Myosin-7 (MYH7) OT4Z9T8N MYH7_HUMAN Decreases Expression [31]
Myosin-6 (MYH6) OT3YNCH1 MYH6_HUMAN Decreases Expression [31]
Troponin T, slow skeletal muscle (TNNT1) OT8PBOAR TNNT1_HUMAN Decreases Expression [31]
Receptor tyrosine-protein kinase erbB-3 (ERBB3) OTRSST0A ERBB3_HUMAN Decreases Expression [31]
Sarcoplasmic reticulum histidine-rich calcium-binding protein (HRC) OTDLEJ4T SRCH_HUMAN Decreases Expression [31]
Tumor necrosis factor receptor superfamily member 6 (FAS) OTP9XG86 TNR6_HUMAN Increases Expression [31]
Sodium/potassium-transporting ATPase subunit alpha-2 (ATP1A2) OTCF8OWW AT1A2_HUMAN Decreases Expression [31]
Potassium voltage-gated channel subfamily KQT member 1 (KCNQ1) OT8SPJNX KCNQ1_HUMAN Decreases Expression [31]
cAMP-dependent protein kinase catalytic subunit PRKX (PRKX) OTDAC6Z0 PRKX_HUMAN Increases Expression [31]
Myomesin-2 (MYOM2) OTD2UOXW MYOM2_HUMAN Decreases Expression [31]
Inward rectifier potassium channel 2 (KCNJ2) OT2OQEZS KCNJ2_HUMAN Increases Expression [31]
Actin, alpha skeletal muscle (ACTA1) OTOVGLPG ACTS_HUMAN Decreases Expression [31]
Iroquois-class homeodomain protein IRX-4 (IRX4) OT0TV6WK IRX4_HUMAN Decreases Expression [31]
Ankyrin-2 (ANK2) OTWB4R1Y ANK2_HUMAN Decreases Expression [31]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Increases Expression [31]
Potassium voltage-gated channel subfamily H member 2 (KCNH2) OTZX881H KCNH2_HUMAN Decreases Expression [31]
Dual specificity protein phosphatase 4 (DUSP4) OT6WAO12 DUS4_HUMAN Increases Expression [31]
Sodium channel protein type 5 subunit alpha (SCN5A) OTGYZWR6 SCN5A_HUMAN Decreases Expression [31]
Protein phosphatase 1 regulatory subunit 3A (PPP1R3A) OTJL9VYP PPR3A_HUMAN Decreases Expression [31]
Caveolae-associated protein 4 (CAVIN4) OTB1DM2C CAVN4_HUMAN Decreases Expression [31]
Nebulin-related-anchoring protein (NRAP) OTO6H3YF NRAP_HUMAN Decreases Expression [31]
Ryanodine receptor 2 (RYR2) OT0PF19E RYR2_HUMAN Decreases Expression [31]
Growth/differentiation factor 15 (GDF15) OTWQN50N GDF15_HUMAN Increases Expression [31]
Histone-lysine N-methyltransferase PRDM16 (PRDM16) OT0BGA27 PRD16_HUMAN Decreases Expression [31]
Voltage-dependent calcium channel subunit alpha-2/delta-2 (CACNA2D2) OTFJXVQQ CA2D2_HUMAN Decreases Expression [31]
Atrial natriuretic peptide-converting enzyme (CORIN) OT4SK7DK CORIN_HUMAN Decreases Expression [31]
Baculoviral IAP repeat-containing protein 5 (BIRC5) OTILXZYL BIRC5_HUMAN Increases Expression [42]
Myc proto-oncogene protein (MYC) OTPV5LUK MYC_HUMAN Decreases Expression [41]
Glucocorticoid receptor (NR3C1) OTCI2YDI GCR_HUMAN Decreases Activity [43]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Affects Activity [44]
Cytochrome P450 1A1 (CYP1A1) OTE4EFH8 CP1A1_HUMAN Decreases Activity [45]
Retinoic acid receptor alpha (RARA) OT192V9V RARA_HUMAN Affects Mutagenesis [46]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [41]
Retinoic acid receptor beta (RARB) OT367U3E RARB_HUMAN Increases Expression [47]
Histone H2AX (H2AX) OT18UX57 H2AX_HUMAN Increases Expression [48]
Protein PML (PML) OT6SM2GD PML_HUMAN Affects Mutagenesis [46]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [49]
Caspase-2 (CASP2) OTUDYSPP CASP2_HUMAN Increases Expression [50]
Caspase-7 (CASP7) OTAPJ040 CASP7_HUMAN Increases Activity [49]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [49]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Increases Activity [49]
Serine-protein kinase ATM (ATM) OTQVOHLT ATM_HUMAN Decreases Expression [51]
Baculoviral IAP repeat-containing protein 2 (BIRC2) OTFXFREP BIRC2_HUMAN Decreases Expression [32]
Sequestosome-1 (SQSTM1) OTGY5D5J SQSTM_HUMAN Decreases Expression [52]
Beclin-1 (BECN1) OT4X293M BECN1_HUMAN Decreases Expression [52]
Caspase-8 (CASP8) OTA8TVI8 CASP8_HUMAN Increases Activity [49]
Cytochrome P450 1B1 (CYP1B1) OTYXFLSD CP1B1_HUMAN Decreases Activity [45]
Autophagy protein 5 (ATG5) OT4T5SMS ATG5_HUMAN Decreases Expression [52]
Regulator of G-protein signaling 2 (RGS2) OT0FSRW7 RGS2_HUMAN Affects Response To Substance [33]
Mitochondrial pyruvate carrier 2 (MPC2) OT0GHXGG MPC2_HUMAN Affects Response To Substance [33]
Molybdenum cofactor sulfurase (MOCOS) OT0TL3Q5 MOCOS_HUMAN Affects Response To Substance [33]
Tripartite motif-containing protein 2 (TRIM2) OT0V1YVC TRIM2_HUMAN Affects Response To Substance [33]
LEM domain-containing protein 2 (LEMD2) OT0YLT7L LEMD2_HUMAN Affects Response To Substance [53]
Iroquois-class homeodomain protein IRX-1 (IRX1) OT0ZN9EJ IRX1_HUMAN Affects Response To Substance [53]
Insulin-like growth factor-binding protein 7 (IGFBP7) OT1D416P IBP7_HUMAN Affects Response To Substance [33]
Methylosome subunit pICln (CLNS1A) OT1HL9L1 ICLN_HUMAN Affects Response To Substance [33]
D-3-phosphoglycerate dehydrogenase (PHGDH) OT1LMRTG SERA_HUMAN Affects Response To Substance [33]
Bifunctional methylenetetrahydrofolate dehydrogenase/cyclohydrolase, mitochondrial (MTHFD2) OT1LQSGX MTDC_HUMAN Affects Response To Substance [33]
3',5'-cyclic-AMP phosphodiesterase 4D (PDE4D) OT1RWFV0 PDE4D_HUMAN Affects Response To Substance [33]
TBC1 domain family member 8 (TBC1D8) OT2011SS TBCD8_HUMAN Affects Response To Substance [33]
Protein FAM117A (FAM117A) OT2FBGGV F117A_HUMAN Affects Response To Substance [33]
Protein transport protein Sec31A (SEC31A) OT2U42AC SC31A_HUMAN Affects Response To Substance [33]
DNA-binding protein SATB2 (SATB2) OT2W80XC SATB2_HUMAN Affects Response To Substance [33]
Large neutral amino acids transporter small subunit 1 (SLC7A5) OT2WPVXD LAT1_HUMAN Affects Response To Substance [33]
Very long chain fatty acid elongase 5 (ELOVL5) OT375W1Z ELOV5_HUMAN Affects Response To Substance [53]
Nuclear receptor subfamily 4 group A member 2 (NR4A2) OT3F9IR2 NR4A2_HUMAN Affects Response To Substance [33]
Solute carrier organic anion transporter family member 4A1 (SLCO4A1) OT3J1G7H SO4A1_HUMAN Affects Response To Substance [33]
Fatty acid CoA ligase Acsl3 (ACSL3) OT3MWER1 ACSL3_HUMAN Affects Response To Substance [33]
Leucine-rich repeat transmembrane protein FLRT3 (FLRT3) OT3XMZU3 FLRT3_HUMAN Affects Response To Substance [33]
ELAV-like protein 4 (ELAVL4) OT3YH6J6 ELAV4_HUMAN Affects Response To Substance [53]
Angiomotin-like protein 1 (AMOTL1) OT40G45S AMOL1_HUMAN Affects Response To Substance [53]
High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A (PDE8A) OT4RF9Z4 PDE8A_HUMAN Affects Response To Substance [33]
PRELI domain containing protein 3B (PRELID3B) OT4TRT4K PLD3B_HUMAN Affects Response To Substance [33]
Argininosuccinate synthase (ASS1) OT4ZMG0Q ASSY_HUMAN Affects Response To Substance [33]
DNA topoisomerase 1 (TOP1) OT51O0CF TOP1_HUMAN Increases ADR [54]
Centrosomal protein 15 (CEP15) OT52961J CEP15_HUMAN Affects Response To Substance [33]
Succinyl-CoA:3-ketoacid coenzyme A transferase 1, mitochondrial (OXCT1) OT536PE7 SCOT1_HUMAN Affects Response To Substance [33]
Ubiquitin-like protein ISG15 (ISG15) OT53QQ7N ISG15_HUMAN Affects Response To Substance [33]
cAMP-responsive element-binding protein-like 2 (CREBL2) OT58JBNU CRBL2_HUMAN Affects Response To Substance [33]
PACRG-like protein (PACRGL) OT5DEP0X PACRL_HUMAN Affects Response To Substance [53]
Isocitrate dehydrogenase subunit alpha, mitochondrial (IDH3A) OT5QQB5L IDH3A_HUMAN Affects Response To Substance [33]
G antigen 6 (GAGE6) OT5WRC1N GAGE6_HUMAN Affects Response To Substance [33]
Melanoma-associated antigen D1 (MAGED1) OT6EOLFC MAGD1_HUMAN Affects Response To Substance [33]
Laminin subunit beta-1 (LAMB1) OT6J9LJR LAMB1_HUMAN Affects Response To Substance [33]
Glutathione peroxidase 3 (GPX3) OT6PK94R GPX3_HUMAN Affects Response To Substance [33]
Band 4.1-like protein 2 (EPB41L2) OT6UABPM E41L2_HUMAN Affects Response To Substance [53]
Monocarboxylate transporter 7 (SLC16A6) OT7BIIZX MOT7_HUMAN Affects Response To Substance [33]
Homeobox protein engrailed-2 (EN2) OT7EZCM2 HME2_HUMAN Affects Response To Substance [33]
Exosome complex exonuclease RRP44 (DIS3) OT7UPHJS RRP44_HUMAN Affects Response To Substance [33]
Protein LBH (LBH) OT87AT1X LBH_HUMAN Affects Response To Substance [33]
G1/S-specific cyclin-D1 (CCND1) OT8HPTKJ CCND1_HUMAN Increases ADR [54]
Secreted frizzled-related protein 4 (SFRP4) OT8PQUVB SFRP4_HUMAN Affects Response To Substance [53]
Mesoderm-specific transcript homolog protein (MEST) OT8Q4U8Y MEST_HUMAN Affects Response To Substance [33]
Asparagine synthetase (ASNS) OT8R922G ASNS_HUMAN Affects Response To Substance [33]
Exostosin-like 2 (EXTL2) OT8U672K EXTL2_HUMAN Affects Response To Substance [33]
Phospholipid-transporting ATPase ABCA1 (ABCA1) OT94G6BQ ABCA1_HUMAN Affects Response To Substance [33]
Frizzled-2 (FZD2) OT952ML1 FZD2_HUMAN Affects Response To Substance [33]
Transcription factor MafF (MAFF) OT9B7MX0 MAFF_HUMAN Affects Response To Substance [53]
Pyridoxal phosphate homeostasis protein (PLPBP) OT9DZ8P6 PLPHP_HUMAN Affects Response To Substance [33]
Splicing factor 45 (RBM17) OT9ROJCL SPF45_HUMAN Decreases Response To Substance [55]
Coxsackievirus and adenovirus receptor (CXADR) OT9ZP02A CXAR_HUMAN Affects Response To Substance [33]
RING finger and CHY zinc finger domain-containing protein 1 (RCHY1) OTAE7504 ZN363_HUMAN Affects Response To Substance [33]
Transgelin (TAGLN) OTAEZ0KP TAGL_HUMAN Affects Response To Substance [33]
POM121 and ZP3 fusion protein (POMZP3) OTAH2JOK POZP3_HUMAN Affects Response To Substance [33]
Transmembrane protein 47 (TMEM47) OTAJ4CPX TMM47_HUMAN Affects Response To Substance [33]
RCC1 and BTB domain-containing protein 1 (RCBTB1) OTAYELI8 RCBT1_HUMAN Affects Response To Substance [33]
Collagen alpha-1(XI) chain (COL11A1) OTB0DRMS COBA1_HUMAN Affects Response To Substance [33]
Stearoyl-CoA desaturase (SCD) OTB1073G SCD_HUMAN Affects Response To Substance [33]
Insulin-like growth factor 2 mRNA-binding protein 3 (IGF2BP3) OTB97VIK IF2B3_HUMAN Affects Response To Substance [33]
Cochlin (COCH) OTBEHD89 COCH_HUMAN Affects Response To Substance [33]
Epoxide hydrolase 1 (EPHX1) OTBKWQER HYEP_HUMAN Increases ADR [54]
Spondin-1 (SPON1) OTC06MY4 SPON1_HUMAN Affects Response To Substance [33]
Interferon regulatory factor 7 (IRF7) OTC1A2PQ IRF7_HUMAN Affects Response To Substance [33]
Cocaine esterase (CES2) OTC647SQ EST2_HUMAN Affects Response To Substance [33]
Mothers against decapentaplegic homolog 2 (SMAD2) OTC6VB4K SMAD2_HUMAN Affects Response To Substance [33]
Cystathionine gamma-lyase (CTH) OTC90LA0 CGL_HUMAN Affects Response To Substance [33]
KRR1 small subunit processome component homolog (KRR1) OTCMJ3K3 KRR1_HUMAN Affects Response To Substance [33]
Early growth response protein 1 (EGR1) OTCP6XGZ EGR1_HUMAN Affects Response To Substance [33]
Interferon-stimulated gene 20 kDa protein (ISG20) OTCWRJJW ISG20_HUMAN Affects Response To Substance [33]
Tropomyosin alpha-1 chain (TPM1) OTD73X6R TPM1_HUMAN Affects Response To Substance [33]
Spondin-2 (SPON2) OTE7JLNM SPON2_HUMAN Affects Response To Substance [33]
Interferon-induced transmembrane protein 1 (IFITM1) OTECO1G8 IFM1_HUMAN Affects Response To Substance [33]
Syndecan-2 (SDC2) OTEEHY1D SDC2_HUMAN Affects Response To Substance [33]
Schwannomin-interacting protein 1 (SCHIP1) OTF3FR4A SCHI1_HUMAN Affects Response To Substance [33]
NADH dehydrogenase iron-sulfur protein 5 (NDUFS5) OTF40UYJ NDUS5_HUMAN Affects Response To Substance [33]
G antigen 7 (GAGE7) OTF8BTR9 GAGE7_HUMAN Affects Response To Substance [33]
Dehydrogenase/reductase SDR family member 2, mitochondrial (DHRS2) OTFHWIY8 DHRS2_HUMAN Affects Response To Substance [33]
Fatty acid synthase (FASN) OTFII9KG FAS_HUMAN Decreases Response To Substance [56]
Laminin subunit alpha-2 (LAMA2) OTFROQWE LAMA2_HUMAN Affects Response To Substance [53]
Squalene synthase (FDFT1) OTGDISIT FDFT_HUMAN Affects Response To Substance [33]
Double-stranded RNA-specific editase 1 (ADARB1) OTGKSZEV RED1_HUMAN Affects Response To Substance [33]
Chordin-like protein 1 (CHRDL1) OTGMWVVA CRDL1_HUMAN Affects Response To Substance [33]
Cytotoxic granule associated RNA binding protein TIA1 (TIA1) OTGPN3P8 TIA1_HUMAN Affects Response To Substance [33]
Voltage-gated potassium channel subunit beta-2 (KCNAB2) OTH115IE KCAB2_HUMAN Affects Response To Substance [33]
Nidogen-2 (NID2) OTHC33FF NID2_HUMAN Affects Response To Substance [33]
Endothelial lipase (LIPG) OTHEE942 LIPG_HUMAN Affects Response To Substance [33]
Chemokine-like factor (CKLF) OTHLPHA0 CKLF_HUMAN Affects Response To Substance [33]
E3 ubiquitin-protein ligase MYCBP2 (MYCBP2) OTHODA1F MYCB2_HUMAN Affects Response To Substance [33]
DNA damage-inducible transcript 4 protein (DDIT4) OTHY8SY4 DDIT4_HUMAN Affects Response To Substance [33]
Basal cell adhesion molecule (BCAM) OTHZOPSD BCAM_HUMAN Affects Response To Substance [33]
Melanoma-associated antigen 6 (MAGEA6) OTI8S0O2 MAGA6_HUMAN Affects Response To Substance [33]
Laminin subunit gamma-1 (LAMC1) OTIG527N LAMC1_HUMAN Affects Response To Substance [33]
Leucine-rich repeat-containing G-protein coupled receptor 4 (LGR4) OTIMWEK5 LGR4_HUMAN Affects Response To Substance [33]
Lysosomal acid lipase/cholesteryl ester hydrolase (LIPA) OTIOLNHE LICH_HUMAN Affects Response To Substance [33]
Runt-related transcription factor 3 (RUNX3) OTITK1XD RUNX3_HUMAN Affects Response To Substance [33]
Lymphocyte function-associated antigen 3 (CD58) OTIUGMGS LFA3_HUMAN Affects Response To Substance [33]
Insulin-like growth factor-binding protein 3 (IGFBP3) OTIX63TX IBP3_HUMAN Affects Response To Substance [33]
Nuclear receptor-interacting protein 1 (NRIP1) OTIZOJQV NRIP1_HUMAN Affects Response To Substance [33]
Protein S100-P (S100P) OTJCXNJG S100P_HUMAN Affects Response To Substance [33]
Ectoderm-neural cortex protein 1 (ENC1) OTJEUB6U ENC1_HUMAN Affects Response To Substance [33]
Transcriptional activator Myb (MYB) OTJH64IV MYB_HUMAN Increases ADR [54]
Trefoil factor 3 (TFF3) OTJJDRTU TFF3_HUMAN Affects Response To Substance [33]
Antigen peptide transporter 1 (TAP1) OTJL27PW TAP1_HUMAN Affects Response To Substance [57]
Calcium/calmodulin-dependent protein kinase II inhibitor 1 (CAMK2N1) OTKCR5XL CK2N1_HUMAN Affects Response To Substance [33]
Aldehyde dehydrogenase, mitochondrial (ALDH2) OTKJ9I3N ALDH2_HUMAN Affects Response To Substance [33]
14-3-3 protein sigma (SFN) OTLJCZ1U 1433S_HUMAN Affects Response To Substance [33]
CUGBP Elav-like family member 2 (CELF2) OTLJJ4VT CELF2_HUMAN Affects Response To Substance [33]
Protein CASC3 (CASC3) OTLK3K4U CASC3_HUMAN Affects Response To Substance [53]
Tyrosine-protein kinase Fyn (FYN) OTLSLVZS FYN_HUMAN Affects Response To Substance [33]
Peroxiredoxin-2 (PRDX2) OTLWCY9T PRDX2_HUMAN Affects Response To Substance [33]
Homeobox protein Hox-A5 (HOXA5) OTLWGPQD HXA5_HUMAN Affects Response To Substance [33]
Eukaryotic translation initiation factor 2 subunit 1 (EIF2S1) OTM0GDTP IF2A_HUMAN Affects Response To Substance [33]
Dual specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2) OTMDVWPS DYRK2_HUMAN Affects Response To Substance [33]
Copper-transporting ATPase 1 (ATP7A) OTMR3GXP ATP7A_HUMAN Decreases Response To Substance [58]
Neurofilament heavy polypeptide (NEFH) OTMSCW5I NFH_HUMAN Affects Response To Substance [33]
Death-associated protein kinase 1 (DAPK1) OTNCNUCO DAPK1_HUMAN Affects Response To Substance [33]
Protein phosphatase inhibitor 2 (PPP1R2) OTNLOUQR IPP2_HUMAN Affects Response To Substance [33]
HMG box transcription factor BBX (BBX) OTNQ3QUC BBX_HUMAN Affects Response To Substance [33]
1-acyl-sn-glycerol-3-phosphate acyltransferase epsilon (AGPAT5) OTNY3VMD PLCE_HUMAN Affects Response To Substance [33]
Melanoma-associated antigen D4 (MAGED4B) OTO37U7W MAGD4_HUMAN Affects Response To Substance [33]
Beta-secretase 2 (BACE2) OTO5YQVK BACE2_HUMAN Affects Response To Substance [33]
Receptor tyrosine-protein kinase erbB-2 (ERBB2) OTOAUNCK ERBB2_HUMAN Decreases Response To Substance [59]
Receptor-type tyrosine-protein phosphatase epsilon (PTPRE) OTOD5NID PTPRE_HUMAN Affects Response To Substance [33]
Probable serine carboxypeptidase CPVL (CPVL) OTOJL31C CPVL_HUMAN Affects Response To Substance [33]
Caveolae-associated protein 3 (CAVIN3) OTOLBK79 CAVN3_HUMAN Affects Response To Substance [33]
Ecotropic viral integration site 5 protein homolog (EVI5) OTOPAP55 EVI5_HUMAN Affects Response To Substance [33]
Pre-B-cell leukemia transcription factor 1 (PBX1) OTORABGO PBX1_HUMAN Affects Response To Substance [33]
E3 ubiquitin-protein ligase Mdm2 (MDM2) OTOVXARF MDM2_HUMAN Decreases Response To Substance [60]
GTP cyclohydrolase 1 (GCH1) OTOZ6NSL GCH1_HUMAN Affects Response To Substance [33]
1-phosphatidylinositol 4,5-bisphosphate phosphodiesterase beta-4 (PLCB4) OTPA0QHW PLCB4_HUMAN Affects Response To Substance [33]
G antigen 4 (GAGE4) OTPB5C0O GAGE4_HUMAN Affects Response To Substance [33]
Interleukin-13 receptor subunit alpha-2 (IL13RA2) OTPC2G0X I13R2_HUMAN Affects Response To Substance [33]
Tribbles homolog 1 (TRIB1) OTPEO17G TRIB1_HUMAN Affects Response To Substance [33]
Tumor protein D52 (TPD52) OTPKSK43 TPD52_HUMAN Affects Response To Substance [33]
DNA dC->dU-editing enzyme APOBEC-3C (APOBEC3C) OTPL0AI1 ABC3C_HUMAN Affects Response To Substance [33]
Eukaryotic translation initiation factor 5A-1 (EIF5A) OTQ8DJX5 IF5A1_HUMAN Affects Response To Substance [33]
Clusterin (CLU) OTQGG0JM CLUS_HUMAN Affects Response To Substance [33]
Histone deacetylase 4 (HDAC4) OTQNGD32 HDAC4_HUMAN Affects Response To Substance [33]
Tissue-type plasminogen activator (PLAT) OTQPDNAB TPA_HUMAN Affects Response To Substance [33]
3-oxo-5-alpha-steroid 4-dehydrogenase 1 (SRD5A1) OTQRET2B S5A1_HUMAN Affects Response To Substance [33]
Sal-like protein 2 (SALL2) OTQWI68Q SALL2_HUMAN Affects Response To Substance [33]
G antigen 2A (GAGE2A) OTRAJ80C GAG2A_HUMAN Affects Response To Substance [33]
Actin, gamma-enteric smooth muscle (ACTG2) OTRDWUO0 ACTH_HUMAN Affects Response To Substance [33]
DNA endonuclease RBBP8 (RBBP8) OTRHJ3GI CTIP_HUMAN Affects Response To Substance [33]
Cysteine/serine-rich nuclear protein 2 (CSRNP2) OTRZNC1C CSRN2_HUMAN Affects Response To Substance [53]
Heat shock-related 70 kDa protein 2 (HSPA2) OTSDET7B HSP72_HUMAN Affects Response To Substance [33]
Guanylate cyclase soluble subunit beta-1 (GUCY1B1) OTSHPHVB GCYB1_HUMAN Affects Response To Substance [33]
Bone marrow stromal antigen 2 (BST2) OTU4LCJV BST2_HUMAN Affects Response To Substance [33]
Synaptotagmin-like protein 2 (SYTL2) OTUIOWKL SYTL2_HUMAN Affects Response To Substance [53]
Max-interacting protein 1 (MXI1) OTUQ9E0D MXI1_HUMAN Affects Response To Substance [33]
Fibronectin type-III domain-containing protein 3A (FNDC3A) OTUX3S2I FND3A_HUMAN Affects Response To Substance [33]
HLA class II histocompatibility antigen, DR beta 5 chain (HLA-DRB5) OTUX5TWM DRB5_HUMAN Affects Response To Substance [33]
Prolyl 4-hydroxylase subunit alpha-1 (P4HA1) OTV04QE5 P4HA1_HUMAN Affects Response To Substance [33]
Forkhead box protein F2 (FOXF2) OTV20NGX FOXF2_HUMAN Affects Response To Substance [33]
Nicotinamide phosphoribosyltransferase (NAMPT) OTVJR3GL NAMPT_HUMAN Affects Response To Substance [33]
Poly polymerase tankyrase-1 (TNKS) OTVOUTPX TNKS1_HUMAN Affects Response To Substance [33]
ADP-ribose glycohydrolase MACROD1 (MACROD1) OTWFEVRW MACD1_HUMAN Affects Response To Substance [33]
Sorbin and SH3 domain-containing protein 1 (SORBS1) OTWH8762 SRBS1_HUMAN Affects Response To Substance [33]
S-adenosylhomocysteine hydrolase-like protein 1 (AHCYL1) OTX8L3M5 SAHH2_HUMAN Affects Response To Substance [33]
Insulin-like growth factor 1 receptor (IGF1R) OTXJIF13 IGF1R_HUMAN Affects Response To Substance [61]
Ras-related GTP-binding protein D (RRAGD) OTXLVWAH RRAGD_HUMAN Affects Response To Substance [53]
SWI/SNF-related matrix-associated actin-dependent regulator of chromatin subfamily E member 1-related (HMG20B) OTY94WRA HM20B_HUMAN Affects Response To Substance [33]
Bone morphogenetic protein 7 (BMP7) OTYATP2K BMP7_HUMAN Affects Response To Substance [33]
Glutamine synthetase (GLUL) OTYGTCGF GLNA_HUMAN Affects Response To Substance [33]
Complement decay-accelerating factor (CD55) OTZ3HWTO DAF_HUMAN Affects Response To Substance [33]
BTB/POZ domain-containing protein 3 (BTBD3) OTZ607YT BTBD3_HUMAN Affects Response To Substance [33]
Zinc finger protein PLAGL1 (PLAGL1) OTZAO900 PLAL1_HUMAN Affects Response To Substance [33]
Ras GTPase-activating protein 1 (RASA1) OTZJ3LP4 RASA1_HUMAN Affects Response To Substance [53]
Ras GTPase-activating-like protein IQGAP1 (IQGAP1) OTZRWTGA IQGA1_HUMAN Affects Response To Substance [33]
------------------------------------------------------------------------------------
⏷ Show the Full List of 230 DOT(s)

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult Acute Basophilic Leukemia DC2VD8I N. A. Phase 2 [62]
Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome DC8MWRX N. A. Phase 2 [63]
Acute Myeloid Leukemia DCX5ANI N. A. Phase 2 [64]
Recurrent Adult Acute Lymphoblastic Leukemia DCXLGKE N. A. Phase 1 [65]
------------------------------------------------------------------------------------

References

1 ClinicalTrials.gov (NCT00470197) Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Relapsed or Refractory Acute Leukemia
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5680).
4 Mitoxantrone FDA Label
5 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7242).
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 Phase 1 and pharmacokinetic study of bolus-infusion flavopiridol followed by cytosine arabinoside and mitoxantrone for acute leukemias. Blood. 2011 Mar 24;117(12):3302-10. doi: 10.1182/blood-2010-09-310862. Epub 2011 Jan 14.
8 Flavopiridol down-regulates antiapoptotic proteins and sensitizes human breast cancer cells to epothilone B-induced apoptosis. Cancer Res. 2003 Jan 1;63(1):93-9.
9 Pharma & Vaccines. Product Development Pipeline. April 29 2009.
10 The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2. Mol Cancer Ther. 2012 Sep;11(9):2033-44.
11 Organic anion transporting polypeptide 1B1: a genetically polymorphic transporter of major importance for hepatic drug uptake. Pharmacol Rev. 2011 Mar;63(1):157-81.
12 Drug-drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi/AUC) ratios. Drug Metab Dispos. 2004 Nov;32(11):1201-8.
13 The cyclin-dependent kinase inhibitor flavopiridol sensitizes human hepatocellular carcinoma cells to TRAIL-induced apoptosis. Int J Mol Med. 2006 Aug;18(2):249-56.
14 Flavopiridol induces cellular FLICE-inhibitory protein degradation by the proteasome and promotes TRAIL-induced early signaling and apoptosis in breast tumor cells. Cancer Res. 2006 Sep 1;66(17):8858-69. doi: 10.1158/0008-5472.CAN-06-0808.
15 Identification and Profiling of Environmental Chemicals That Inhibit the TGF/SMAD Signaling Pathway. Chem Res Toxicol. 2019 Dec 16;32(12):2433-2444. doi: 10.1021/acs.chemrestox.9b00228. Epub 2019 Nov 11.
16 Flavopiridol induces apoptosis in chronic lymphocytic leukemia cells via activation of caspase-3 without evidence of bcl-2 modulation or dependence on functional p53. Blood. 1998 Nov 15;92(10):3804-16.
17 Flavopiridol inhibits smooth muscle cell proliferation in vitro and neointimal formation In vivo after carotid injury in the rat. Circulation. 1999 Aug 10;100(6):659-65. doi: 10.1161/01.cir.100.6.659.
18 Loss of the Bcl-2 phosphorylation loop domain is required to protect human myeloid leukemia cells from flavopiridol-mediated mitochondrial damage and apoptosis. Cancer Biol Ther. 2002 Mar-Apr;1(2):136-44. doi: 10.4161/cbt.58.
19 Transcription inhibition by flavopiridol: mechanism of chronic lymphocytic leukemia cell death. Blood. 2005 Oct 1;106(7):2513-9. doi: 10.1182/blood-2005-04-1678. Epub 2005 Jun 21.
20 Flavopiridol targets c-KIT transcription and induces apoptosis in gastrointestinal stromal tumor cells. Cancer Res. 2006 Jun 1;66(11):5858-66. doi: 10.1158/0008-5472.CAN-05-2933.
21 Flavopiridol enhances human tumor cell radiosensitivity and prolongs expression of gammaH2AX foci. Mol Cancer Ther. 2004 Apr;3(4):409-16.
22 Abrogation of p21 expression by flavopiridol enhances depsipeptide-mediated apoptosis in malignant pleural mesothelioma cells. Clin Cancer Res. 2004 Mar 1;10(5):1813-25. doi: 10.1158/1078-0432.ccr-0901-3.
23 Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. Blood. 2004 Jul 15;104(2):509-18. doi: 10.1182/blood-2003-12-4121. Epub 2004 Mar 23.
24 Flavopiridol mediates cell cycle arrest and apoptosis in esophageal cancer cells. Clin Cancer Res. 1998 Nov;4(11):2885-90.
25 Flavopiridol induces apoptosis and caspase-3 activation of a newly characterized Burkitt's lymphoma cell line containing mutant p53 genes. Blood Cells Mol Dis. 2001 May-Jun;27(3):610-24. doi: 10.1006/bcmd.2001.0428.
26 Flavopiridol induces cell cycle arrest and p53-independent apoptosis in non-small cell lung cancer cell lines. Clin Cancer Res. 1999 Oct;5(10):2925-38.
27 The cyclin-dependent kinase inhibitor flavopiridol induces apoptosis in human leukemia cells (U937) through the mitochondrial rather than the receptor-mediated pathway. Cell Death Differ. 2001 Jul;8(7):715-24. doi: 10.1038/sj.cdd.4400868.
28 Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. Mol Cancer Ther. 2003 Feb;2(2):139-50.
29 Bcl-2 independence of flavopiridol-induced apoptosis. Mitochondrial depolarization in the absence of cytochrome c release. J Biol Chem. 2000 Oct 13;275(41):32089-97. doi: 10.1074/jbc.M005267200.
30 The cyclin-dependent kinase (CDK) inhibitor flavopiridol inhibits glycogen phosphorylase. Arch Biochem Biophys. 2001 Feb 15;386(2):179-87. doi: 10.1006/abbi.2000.2220.
31 Identification of genomic biomarkers for anthracycline-induced cardiotoxicity in human iPSC-derived cardiomyocytes: an in vitro repeated exposure toxicity approach for safety assessment. Arch Toxicol. 2016 Nov;90(11):2763-2777.
32 Upon drug-induced apoptosis in lymphoma cells X-linked inhibitor of apoptosis (XIAP) translocates from the cytosol to the nucleus. Leuk Lymphoma. 2004 Jul;45(7):1429-36. doi: 10.1080/1042819042000198858.
33 Gene expression profiling of 30 cancer cell lines predicts resistance towards 11 anticancer drugs at clinically achieved concentrations. Int J Cancer. 2006 Apr 1;118(7):1699-712. doi: 10.1002/ijc.21570.
34 Mitoxantrone, a topoisomerase II inhibitor, induces apoptosis of B-chronic lymphocytic leukaemia cells. Br J Haematol. 1998 Jan;100(1):142-6.
35 Multidrug resistance protein 1 (MRP1, ABCC1) mediates resistance to mitoxantrone via glutathione-dependent drug efflux. Mol Pharmacol. 2006 Apr;69(4):1499-505.
36 Mammalian drug efflux transporters of the ATP binding cassette (ABC) family in multidrug resistance: A review of the past decade. Cancer Lett. 2016 Jan 1;370(1):153-64.
37 Functional characterization of the human multidrug transporter, ABCG2, expressed in insect cells. Biochem Biophys Res Commun. 2001 Jul 6;285(1):111-7.
38 A distinct "side population" of cells with high drug efflux capacity in human tumor cells. Proc Natl Acad Sci U S A. 2004 Sep 28;101(39):14228-33.
39 FDA label of Mitoxantrone. The 2020 official website of the U.S. Food and Drug Administration.
40 Enhanced in vitro invasiveness and drug resistance with altered gene expression patterns in a human lung carcinoma cell line after pulse selection with anticancer drugs. Int J Cancer. 2004 Sep 10;111(4):484-93. doi: 10.1002/ijc.20230.
41 High-dose mitoxantrone induces programmed cell death or apoptosis in human myeloid leukemia cells. Blood. 1993 Nov 15;82(10):3133-40.
42 [Alteration of expression of survivin in HL-60 cells treated with chemotherapeutic drugs]. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2006 Apr;14(2):347-50.
43 Discovery of selective glucocorticoid receptor modulators by multiplexed reporter screening. Proc Natl Acad Sci U S A. 2009 Mar 24;106(12):4929-34. doi: 10.1073/pnas.0812308106. Epub 2009 Mar 2.
44 Identification of environmental chemicals that activate p53 signaling after in vitro metabolic activation. Arch Toxicol. 2022 Jul;96(7):1975-1987. doi: 10.1007/s00204-022-03291-5. Epub 2022 Apr 18.
45 Association of CYP1A1 and CYP1B1 inhibition in in vitro assays with drug-induced liver injury. J Toxicol Sci. 2021;46(4):167-176. doi: 10.2131/jts.46.167.
46 Evidence for direct involvement of epirubicin in the formation of chromosomal translocations in t(15;17) therapy-related acute promyelocytic leukemia. Blood. 2010 Jan 14;115(2):326-30. doi: 10.1182/blood-2009-07-235051. Epub 2009 Nov 2.
47 The DNA-binding epidermal growth factor-receptor inhibitor PD153035 and other DNA-intercalating cytotoxic drugs reactivate the expression of the retinoic acid receptor-beta tumor-suppressor gene in breast cancer cells. Differentiation. 2007 Nov;75(9):883-90. doi: 10.1111/j.1432-0436.2007.00199.x. Epub 2007 Jul 2.
48 Single pre-treatment with hypericin, a St. John's wort secondary metabolite, attenuates cisplatin- and mitoxantrone-induced cell death in A2780, A2780cis and HL-60 cells. Toxicol In Vitro. 2014 Oct;28(7):1259-73. doi: 10.1016/j.tiv.2014.06.011. Epub 2014 Jun 30.
49 Synergistic effects of chemotherapeutic drugs in lymphoma cells are associated with down-regulation of inhibitor of apoptosis proteins (IAPs), prostate-apoptosis-response-gene 4 (Par-4), death-associated protein (Daxx) and with enforced caspase activation. Biochem Pharmacol. 2003 Sep 1;66(5):711-24. doi: 10.1016/s0006-2952(03)00410-6.
50 Topoisomerase I and II inhibitors control caspase-2 pre-messenger RNA splicing in human cells. Mol Cancer Res. 2004 Jan;2(1):53-61.
51 Dynamic coregulatory complex containing BRCA1, E2F1 and CtIP controls ATM transcription. Cell Physiol Biochem. 2012;30(3):596-608. doi: 10.1159/000341441. Epub 2012 Jul 27.
52 Autophagy (but not metabolism) is a key event in mitoxantrone-induced cytotoxicity in differentiated AC16 cardiac cells. Arch Toxicol. 2023 Jan;97(1):201-216. doi: 10.1007/s00204-022-03363-6. Epub 2022 Oct 10.
53 Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival. Oncogene. 2005 Nov 17;24(51):7542-51. doi: 10.1038/sj.onc.1208908.
54 ADReCS-Target: target profiles for aiding drug safety research and application. Nucleic Acids Res. 2018 Jan 4;46(D1):D911-D917. doi: 10.1093/nar/gkx899.
55 Human splicing factor SPF45 (RBM17) confers broad multidrug resistance to anticancer drugs when overexpressed--a phenotype partially reversed by selective estrogen receptor modulators. Cancer Res. 2005 Aug 1;65(15):6593-600. doi: 10.1158/0008-5472.CAN-03-3675.
56 A new mechanism of drug resistance in breast cancer cells: fatty acid synthase overexpression-mediated palmitate overproduction. Mol Cancer Ther. 2008 Feb;7(2):263-70. doi: 10.1158/1535-7163.MCT-07-0445.
57 Gene expressions associated with chemosensitivity in human hepatoma cells. Hepatogastroenterology. 2007 Mar;54(74):489-92.
58 Copper-transporting P-type ATPase, ATP7A, confers multidrug resistance and its expression is related to resistance to SN-38 in clinical colon cancer. Cancer Res. 2007 May 15;67(10):4860-8. doi: 10.1158/0008-5472.CAN-06-3096.
59 Up-regulation of breast cancer resistance protein plays a role in HER2-mediated chemoresistance through PI3K/Akt and nuclear factor-kappa B signaling pathways in MCF7 breast cancer cells. Acta Biochim Biophys Sin (Shanghai). 2011 Aug;43(8):647-53. doi: 10.1093/abbs/gmr050. Epub 2011 Jun 28.
60 Effect of a single nucleotide polymorphism in the murine double minute 2 promoter (SNP309) on the sensitivity to topoisomerase II-targeting drugs. Cancer Res. 2007 Jun 15;67(12):5831-9. doi: 10.1158/0008-5472.CAN-06-4533.
61 Silencing of the IGF1R gene enhances sensitivity to DNA-damaging agents in both PTEN wild-type and mutant human prostate cancer. Cancer Gene Ther. 2005 Jan;12(1):90-100. doi: 10.1038/sj.cgt.7700775.
62 ClinicalTrials.gov (NCT00407966) Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
63 ClinicalTrials.gov (NCT00795002) Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
64 ClinicalTrials.gov (NCT02520011) Alvocidib Biomarker-driven Phase 2 AML Study
65 ClinicalTrials.gov (NCT00016016) Flavopiridol, Cytarabine, and Mitoxantrone in Treating Patients With Acute Leukemia